

Supplemental data

Impairment of leukemia initiating self-renewal by a novel selective small molecule CBP/p300 bromodomain inhibitor

Sarah Picaud, Oleg Fedorov, Angeliki Thanasopoulou, Katharina Leonards, Katherine Jones, Julia Meier, Heidi Olzscha, Octovia Monteiro, Sarah Martin, Martin Philpott, Anthony Tumber, Panagis Filippakopoulos, Clarence Yapp, Christopher Wells, Ka Hing Che, Andrew Bannister, Samuel Robson, Umesh Kumar, Nigel Parr, Kevin Lee, Dave Lugo, Philip Jeffrey, Simon Taylor, Chas Bountra, Paul Brennan, Duncan Hay, Danette L. Daniels, Marjeta Urh, Alison O'Mahony, Sharlene Velichko, Susanne Müller, Nicholas B. La Thangue, Tony Kouzarides, Rab Prinjha, Jürg Schwaller, Stefan Knapp.


Supplemental Table 1: I-CBP112 ΔT_m data for bromodomains	page: 2
Supplemental Table 2: I-CBP112 ITC data	page: 3
Supplemental Table 3: Selectivity screening data (outside BRD family)	page: 4
Supplemental Table 4: ITC data (peptides)	page: 8
Supplemental Table 5: Data collection and refinement statistics	page: 10
Supplemental Table 6: CBP and EP300 mutations in cell lines	page: 17
Supplemental Table 7: I-CBP112 deregulated genes (3d KASUMI-1)	page: 27
Supplemental Table 8: I-CBP112 deregulated genes (3d MOLM13)	page: 36
Supplemental Table 9: I-CBP112 deregulated genes (3d SEM)	page: 39
Supplemental Figure 1: BLI evaluation of I-CBP112 selectivity	page: 2
Supplemental Figure 2: FRAP data	page: 9
Supplemental Figure 3: BioMAP data for I-CBP112	page: 11
Supplemental Figure 4: Effects on MLL-AF9 and NUP98-HOXA9	page: 14
Supplemental Figure 5: Immunophenotype of injected MLL-AF9 cells	page: 15
Supplemental Figure 6: Limiting dilution transplantation	page: 16
Supplemental Figure 7: Cell survival data	page: 17
Supplemental Figure 8: Colony formation in human leukemic cell lines	page: 18
Supplemental Figure 9: Prolonged exposure of KASUMI-1 to I-CBP112	page: 19
Supplemental Figure 10: Prolonged exposure of MOLM13 to I-CBP112	page: 20
Supplemental Figure 11: Prolonged exposure of SEM to I-CBP112	page: 21
Supplemental Figure 12: Differentiation of CD34 ⁺ cells	page: 21
Supplemental Figure 13: Validation of the synergistic effect	page: 23
Supplemental Figure 14: γ -H2Ax immunohistochemistry	page: 26
Supplemental Figure 15: Expression changes in KASUMI-1	page: 49
Supplemental Figure 16: ChIP qPCR data	page: 50

Supplemental Table 1: Temperature shift data of I-CBP112 against a panel of human bromodomains. The values represent the average of three independent measurements.

Protein	ΔT_m [°C]	Protein	ΔT_m [°C]
1 ASH1L	0.24 ± 0.26	23 KIAA1240	0.05 ± 0.14
2 ATAD2	0.14 ± 0.56	24 LOC93349#	0.65 ± 0.61
3 BAZ1A	0.16 ± 1.20	25 PB1(1)	0.77 ± 0.80
4 BAZ2A	0.17 ± 0.41	26 PB1(2)	0.13 ± 0.28
5 BAZ2B	0.12 ± 0.16	27 PB1(3)	-0.24 ± 0.23
6 BRD1	0.43 ± 0.35	28 PB1(4)	0.28 ± 0.62
7 BRD2(1)	1.35 ± 0.48	29 PB1(5)	0.11 ± 0.20
8 BRD2(2)	0.87 ± 0.28	30 PB1(6)	-0.04 ± 0.28
9 BRD3(1)	1.55 ± 0.44	31 PCAF	-0.01 ± 0.29
10 BRD3(2)	0.94 ± 0.25	32 PHIP(2)	0.62 ± 0.49
11 BRD4(1)	2.09 ± 0.41	33 SMARCA2	-0.02 ± 0.15
12 BRD4(2)	0.58 ± 0.20	34 SMARCA4	0.36 ± 0.16
13 BRDT(1)	0.68 ± 0.43	35 SP140	-0.64 ± 0.86
14 BRD9	0.20 ± 0.17	36 TAF1(1)	0.16 ± 0.17
15 BRPF1	0.19 ± 0.60	37 TAF1(2)	-0.13 ± 0.30
16 BRPF3	0.07 ± 0.63	38 TAF1L(1)	0.12 ± 0.40
17 BRWD3(2)	0.64 ± 1.16	39 TAF1L(2)	-0.04 ± 0.45
18 CECR2	0.43 ± 0.19	40 TIF1A#	0.32 ± 0.31
19 CREBBP	7.77 ± 0.53	41 TIF1A(PHD)	0.26 ± 0.68
20 EP300	8.69 ± 0.28	42 TRIM28#	-0.42 ± 0.51
21 FALZ	0.63 ± 0.14	43 TRIM66	0.15 ± 0.41
22 GCN5L2	0.54 ± 0.27	44 WDR9(2)	-0.33 ± 0.56

PDH/BRD dual domain construct

Supplemental Figure 1



Supplemental Figure 1: BLI evaluation of i-CBP112 selectivity using BLI. 42 human bromodomains were biotinylated *in vivo* by fusion with the biotinylation sequence (SSKGGYGLNDIFEAQKIEWHE) inserted at the C-terminus and co-expression of BirA using a pACYC co-expression vector. Bromodomains immobilized on streptavidine tips were screened at two concentrations (0.2 and 2.0 μM). The maximum response reached at this concentration is shown. Strong binding was only observed for CBP/p300. Weaker interactions are also evident for BET bromodomains.

Supplemental Table 2:

Protein	[P] (μM)	[L] (μM)	N	K_d (nM)	ΔH^{obs} (cal/mol)	T ΔS (kcal/mol)	ΔG (kcal/mol)
CBP	195	20	0.98	151	-9031 ± 25.8	-0.0380	-8.99
EP300	248	20	0.97	167	-9291 ± 34.5	-0.3456	-8.94
BRD4(1)	450	17	1.01	5587	-5363 ± 129.0	1.5638	-6.92
BRD4(2)	440	17	0.96	20000	-3704 ± 330.4	2.4912	-6.19

Errors shown are errors of the non-linear least square fits. Measurements have been carried out at 15 °C. [P] and [L] show the protein and ligand concentration used in the different experiments.

Supplemental Table 2: Isothermal Titration Calorimetry measurements of the interaction of I-CBP112 with bromodomains.

Supplemental Table 3A (CEREP selectivity data (enzymes))

Enzyme assay	%[Inhibition] at 10 μM (I-CBP112) (S)	%[Inhibition] at 10 μM (I-CBP112) (R)
COX1	-33	-4
COX2	2	14
inducible NOS	-35	-37
PDE2A1	4	2
PDE3B	0	0
PDE4D2	14	15
PDE5 (non-selective)	-2	-1
PDE6 (non-selective)	8	6
ACE	-7	-21
ACE-2	7	6
BACE-1 (beta -secretase)	4	-1
caspase-3	-7	-6
HIV-1 protease	-3	-1
neutral endopeptidase (h)	2	6
MMP-1	-11	-17
MMP-2	16	12
MMP-9	-15	-2
Abl kinase	3	0
CaMK2alpha	0	0
CDK2 (cycA)	-1	2
ERK2 (P42mapk)	7	-1
FLT-1 kinase (VEGFR1)	-3	5
Fyn kinase	-4	-3
IRK (InsR)	20	-1
Lyn A kinase	-1	-7
p38alpha kinase	-1	-1
ZAP70 kinase	-2	11
acetylcholinesterase	21	28
COMT (catechol- O-methyl transferase)	-4	5
xanthine oxidase/ superoxide O ₂ - scavenging	5	-8
ATPase (Na ⁺ /K ⁺)	0	0

Supplemental Table 3 B (CEREP selectivity data (GPCRs and ion channels))

GPCR Assay	%[I] at 10 μM (I-CBP112) (S)	%[I] at 10 μM (I-CBP112) (R)
A1 (ago. r.)	4	-5
A2A (ago. r.)	11	1
A2B (anta. r.)	-4	-13
A3 (ago. r.)	-7	-4
alpha 1A (anta. r.)	89	89
alpha 1B (anta. r.)	21	52
alpha 2A (anta. r.)	18	24
alpha 2B (anta. r.)	-9	49
alpha 2C (anta. r.)	39	50
beta 1 (ago. r.)	-4	-9
beta 2 (ago. r.)	0	1
beta 3 (anta. r.)	-3	-15
AT1 (anta. r.)	21	9
AT2 (ago. r.)	-8	-1
APJ (apelin) (ago. r.)	-3	-1
BZD (central) (ago. r.)	-5	-12
BB3 (ago. r.)	-10	-22
B2 (ago. r.)	-5	-7
CB1 (ago. r.)	-5	0
CB2 (ago. r.)	2	5
CCK1 (CCKA) (ago. r.)	6	-6
CCK2 (CCKB) (ago. r.)	-4	-10
CRF1 (ago. r.)	-19	-26
D1 (anta. r.)	11	17
D2S (ago. r.)	12	28
D3 (anta. r.)	-2	18
ETA (ago. r.)	-2	-27
ETB (ago. r.)	-5	-2
GABAA1 (alpha 1, β 2, γ 2) (ago. r.)	12	-6
GABAB(1b) (anta. r.)	0	4
glucagon (ago. r.)	-8	-16
AMPA (ago. r.)	-14	-14
kainate (ago. r.)	-7	-2
NMDA (anta. r.)	-16	0
glycine (strychnine-insensitive)(anta. r.)	0	3
TNF-alpha (ago. r.)	-4	14
CCR2 (ago. r.)	-10	0
H1 (anta. r.)	5	-8
H2 (anta. r.)	3	7
H3 (ago. r.)	3	-5
H4 (ago. r.)	2	-3

BLT1 (LTB4) (ago. r.)	0	-1
CysLT1 (LTD4) (ago. r.)	-12	-21
MCH1 (ago. r.)	7	-9
MC1(ago. r.)	0	0
MC3 (ago. r.)	-6	-21
MC4 (ago. r.)	-10	0
MT1 (ML1A) (ago. r.)	-15	-11
MT3 (ML2) (ago. r.)	45	54
MAO-A (anta. r.)	-6	-5
motilin (ago. r.)	-1	2
M1 (anta. r.)	38	48
M2 (anta. r.)	67	49
M3 (anta. r.)	20	35
M4 (anta. r.)	74	63
NK1 (ago. r.)	4	8
NK2 (ago. r.)	-8	2
Y1 (ago. r.)	-10	-10
N neuronal alpha 4beta 2 (ago. r.)	23	20
N muscle-type (anta. r.)	19	19
delta 2 (DOP) (ago. r.)	8	-7
kappa (KOP) (ago. r.)	-6	-9
mu (MOP) (ago. r.)	3	5
NOP (ORL1) (ago. r.)	6	1
PPARgamma (ago. r.)	-8	-9
PAF (ago. r.)	9	11
PCP (anta. r.)	-4	3
EP2 (ago. r.)	9	8
FP (ago. r.)	-4	-5
IP (PGI2) (ago. r.)	-6	-15
LXRbeta (ago. r.)	15	15
5-HT1A (ago. r.)	16	58
5-HT1B (anta. r.)	9	46
5-HT1D (ago. r.)	18	-1
5-HT2A (ago. r.)	30	62
5-HT2B (ago. r.)	-17	7
5-HT2C (ago. r.)	11	52
5-HT3 (anta. r.)	3	-11
5-HT4e (anta. r.)	32	18
5-HT6 (ago. r.)	-6	-3
5-HT7 (ago. r.)	6	10
sigma (non-selective) (ago. r.)	46	15
sst1 (ago. r.)	15	16
sst4 (ago. r.)	-7	-7
GR (ago. r.)	-5	-1

ERalpha (agonist fluoligand)	5	2
AR (ago. r.)	-3	-24
TR (TH) (ago. r.)	-26	-29
UT (ago. r.)	8	21
VPAC1 (VIP1) (ago. r.)	-2	1
V1a (ago. r.)	4	-2
V2 (ago. r.)	4	-6
Ca ²⁺ channel (L, dihydropyridine site) (anta. r.)	4	7
Ca ²⁺ channel (L, diltiazem site) (benzothiazepines)(anta. r.)	38	12
Ca ²⁺ channel (L, verapamil site) (phenylalkylamine) (anta. r.)	19	23
Ca ²⁺ channel (N) (anta. r.)	13	-15
SKCa channel (anta. r.)	6	4
Na ⁺ channel (site 2) (anta. r.)	11	8
Cl ⁻ channel (GABA-gated) (anta. r.)	-48	-15
norepinephrine transporter (anta. r.)	0	-8
dopamine transporter (anta. r.)	-3	-9
GABA transporter (anta. r.)	0	3
choline transporter (CHT1) (anta. r.)	8	4
5-HT transporter (anta. r.)	-30	-9

Assay data were provided by Cerep. Details on assay conditions and control compounds used can be found on the Cerep home page (<http://www.cerep.fr/Cerep/Users/index.asp>).

Data are shown as [%] inhibition at 10 μ M compound concentration, (ago.r.) means (agonist radioligand) and (anta. r.) (antagonist radioligand), respectively.

Supplemental Table 4:


Protein	Peptide	K_D (μM)	ΔH^{obs} (kcal/mol)	N	T ΔS (kcal/mol)	ΔG (kcal/mol)
CBP	H3K56	13.8 \pm 0.4	-7.9 \pm 0.1	0.966	-1.6	-6.30
	H4K5/K8	31.0 \pm 0.5	-13.7 \pm 0.2	0.581	-7.8	-5.85
	H4K5/K8/K12	29.0 \pm 0.7	-14.8 \pm 0.3	0.508	-8.9	-5.89
P300	H4K5/K8/K12	28.7 \pm 0.6	-14.1 \pm 0.2	0.602	-8.2	-5.90

Histone peptide sequences used in Isothermal Titration Calorimetry experiments.

Histone Marks	Peptide Sequence
H3K56	IRRYQK _{ac} STELL
H4K5/K8	SGRGK _{ac} GGK _{ac} GLGY
H4K5/K8/K12	RGK _{ac} GGK _{ac} GLGK _{ac} GGY

Supplemental Table 4: – Isothermal Titration Calorimetry of human CBP and p300 bromodomains with acetylated histone peptides. Titrations were carried out in 50 mM HEPES pH 7.5 (at 25 °C), 150 mM NaCl and 10 °C while stirring at 1000 rpm. Peptides were titrated into the protein solution.

Supplemental Figure 2




Supplemental Figure 2: FRAP data. A: FRAP experiment showing nuclei of 3xCPB_{BRD}/GFP transfected cells treated with DMSO (top row), 3x BRD^{N1168F}/GFP transfected cells treated with DMSO (middle row) as well as 3xCPB_{BRD}/GFP transfected cells treated with and 1.0 μM I-CBP112. All cells were treated with 2.5 μM SAHA to increase global acetylation levels. The bleached area is indicated by a red circle. **B:** Recovery of the normalized fluorescent signal. Shown are recovery curves averaged from at least 10 different nuclei for the different constructs as indicated in the figure capture. Experiments with SAHA treated cells (2.5 μM) are indicated by & and are underlined.

Supplemental Table 5 – Diffraction data collection and structure refinement statistics

Data Collection	
PDB ID	4NR6
Protein/Ligand	CBP/I-CBP112
Space group	C2
Cell dimensions: a, b, c (Å)	89.71 34.14 40.40
α, β, γ (deg)	90.00 93.00 90.00
Resolution* (Å) (last shell)	1.66 (1.75-1.66)
Unique observations*	14891 (2113)
Completeness* (%)	99.0 (97.9)
Redundancy*	3.4 (3.1)
R _{merge} *	0.063 (0.478)
I/σI*	10.7 (2.1)
Refinement	
Resolution (Å)	1.66
R _{work} / R _{free} (%)	18.1/23.1
Number of atoms (protein/other/water)	971/108/34
B-factors (Å ²) (protein/other/water)21.85	28.75/32.55/29.79
r.m.s.d bonds (Å)	0.015
r.m.s.d angles (°)	1.698
Ramachadran Favoured (%)	100.00
Allowed (%)	0.00
Disallowed (%)	0.00

* Values in parentheses correspond to the highest resolution shell.

Supplemental Figure 3: BioMAP data for I-CBP112.




Supplemental Figure 3: Full Biomap profile for I-CBP112. Monitored markers and cellular systems are described in the table below.

<u>Relevance</u>	<u>Cell Type</u>	<u>Read Out</u>	<u>System</u>
Allergy, Asthma, Autoimmunity	Venular endothelial cells	CCL2/MCP-1, CCL26/Eotaxin-3, CD106/VCAM-1, CD62P/P-Selectin, CD87/uPAR, SRB, VEGFR2,	4H
Allergy, Asthma, Autoimmunity, Oncology	B cells + Peripheral blood mononuclear cells	B cell Proliferation, PBMC Cytotoxicity, Secreted IgG, sIL-17A, sIL-17F, sIL-2, sIL-6, sTNF- α ,	BT
Allergy, Asthma, Fibrosis, Lung Inflammation	Bronchial epithelial cells + Dermal fibroblasts	CCL2/MCP-1, CCL26/Eotaxin-3, CD106/VCAM-1, CD54/ICAM-1, CD90, CXCL8/IL-8, IL-1 α , Keratin 8/18, MMP-1, MMP-3, MMP-9, PAI-I, SRB, tPA, uPA,	BF4T
Autoimmune Disease, Chronic Inflammation	Peripheral blood mononuclear cells + Venular endothelial cells	CCL2/MCP-1, CD38, CD40, CD62E/E-Selectin, CD69, CXCL8/IL-8, CXCL9/MIG, PBMC Cytotoxicity, Proliferation, SRB,	SAg
Cardiovascular Disease, Chronic Inflammation	Venular endothelial cells	CCL2/MCP-1, CD106/VCAM-1, CD141/Thrombomodulin, CD142/Tissue Factor, CD54/ICAM-1, CD62E/E-Selectin, CD87/uPAR, CXCL8/IL-8, CXCL9/MIG, HLA-DR, Proliferation, SRB,	3C
Cardiovascular Disease, Chronic Inflammation	Peripheral blood mononuclear cells + Venular endothelial cells	CCL2/MCP-1, CD106/VCAM-1, CD141/Thrombomodulin, CD142/Tissue Factor, CD40, CD62E/E-Selectin, CD69, CXCL8/IL-8, IL-1 α , M-CSF, sPGE2, SRB, sTNF- α ,	LPS
Cardiovascular Disease, Chronic Inflammation, Restenosis	Macrophages + Venular endothelial cells	CCL2/MCP-1, CCL3/MIP-1 α , CD106/VCAM-1, CD40, CD62E/E-Selectin, CD69, CXCL8/IL-8, IL-1 α , M-CSF, sIL-10, SRB, SRB-Mphg,	IMphg
Cardiovascular Disease, Restenosis	Coronary artery smooth muscle cells	CCL2/MCP-1, CD106/VCAM-1, CD141/Thrombomodulin, CD142/Tissue Factor, CD87/uPAR, CXCL8/IL-8, CXCL9/MIG, HLA-DR, IL-6, LDLR, M-CSF, PAI-I, Proliferation, Serum Amyloid A, SRB,	CASM3C
Chronic Inflammation, Fibrosis	Dermal fibroblasts	CCL2/MCP-1, CD106/VCAM-1, CD54/ICAM-1, Collagen I, Collagen III, CXCL10/IP-10, CXCL11/I-TAC, CXCL8/IL-8, CXCL9/MIG, EGFR, M-CSF, MMP-1, PAI-I, Proliferation_72hr, SRB, TIMP-1, TIMP-2,	HDF3CGF
Chronic Inflammation,	Lung fibroblasts	bFGF, CD106/VCAM-1, Collagen I, Collagen III, Collagen IV, CXCL8/IL-8,	MyoF


Fibrosis, Matrix Remodeling, Wound Healing		Decorin, MMP-1, PAI-I, SRB, TIMP-1, α -SM Actin,	
COPD, Lung Inflammation	Bronchial epithelial cells	CD54/ICAM-1, CD87/uPAR, CXCL10/IP-10, CXCL11/I-TAC, CXCL8/IL-8, CXCL9/MIG, EGFR, HLA-DR, IL-1 α , Keratin 8/18, MMP-1, MMP-9, PAI-I, SRB, tPA, uPA,	BE3C
Dermatitis, Psoriasis	Dermal fibroblasts + Keratinocytes	CCL2/MCP-1, CD54/ICAM-1, CXCL10/IP-10, CXCL8/IL-8, CXCL9/MIG, IL-1 α , MMP-9, PAI-I, SRB, TIMP-2, uPA,	KF3CT

Supplemental Figure 4


A




B




C




D



E




F




Supplemental Figure 4: Effects of I-CBP112 on NUP98-HOXA9 and MLL-AF9 *in vitro* immortalized cells. Differentiation and clonogenic growth of mouse NUP98-HOXA9 and MLL-AF9. **A:** Cytospot images of NUP98-HOXA9 *in vitro* immortalized cells treated with DMSO (upper panel) and 1 μ M I-CBP112 (lower panel). **B:** Cell survival of NUP98-HOXA9 *in vitro* immortalized cells treated with increasing concentration of I-CBP112. **C:** Effect of I-CBP112 on clonogenic growth of NUP98-HOXA9 (first and second plating). **D:** Cytospot images of MLL-AF9 *in vitro* immortalized cells treated with DMSO (upper panel) and 1 μ M I-CBP112 (lower panel). **E:** Cell survival of MLL-AF9 *in vitro* immortalized cells treated with increasing concentration of I-CBP112. **F:** Effect of I-CBP112 on clonogenic growth of MLL-AF9 (first and second plating).

Supplemental Figure 5


MLL-AF9 blasts 5 μ M I-CBP112



MLL-AF9 blasts DMSO- treated




Supplemental Figure 5: Immunophenotype of injected MLL- AF9+ blasts
 Immunophenotype of injected MLL-AF9 cells prior to transplantation into recipient mice. Marker proteins (Gr-1, Mac-1, Fc γ R2/3, c-Kit) have been flow cytometrically analysed.

Supplemental Figure 6: Survival data limiting dilution transplantation

Supplemental Figure 6: Kaplan-Meier diagram showing significantly extended survival of mice injected with different number of I-CBP112 (5 μ M) treated cells (dotted lines) compared to vehicle-treated controls (solid lines). The number of injected cells were **A:** 50 000 cells and **B:** 5 000 cells. P- values were calculated using log- rank (Mantel-Cox) Test, Control group n=5, Treated-group n=4.

Supplemental Figure 7



Supplemental Figure 7: Cell survival of 18 human, leukemic cell lines after 72h in liquid culture. Cell survival data of 18 human leukemic cell lines (**A:** MLL- Fusion+, **B:** MLL- WT) exposed to increasing concentrations of I-CBP112 for 72h in liquid culture. Cell vitality was assessed using WST1 proliferation/survival assays and was plotted as a function of compound (I-CBP112) concentration.

CBP/P300 mutation status of the used cell lines.


Human cell line	Mutation (CCLE)	
	CBP	EP300
K562	-	-
HEL	-	Chr. 22B'UTR'Del
THP1	-	-
RS4;11	-	-
MV4;11	-	-
MOLM13	-	-
SEM	-	-
KOPN8	-	-
PL21	-	-
HL60	-	-
KASUMI-1	-	-
REH	-	-
KG1	-	-
U937	-	-
MONOMAC	-	-
KOCL44	-	-
KOCL45	-	-
SKNO-1	-	-

CBP and EP300 mutations in human leukemic cell lines used in this study. Mutations were retrieved from Cancer Cell Encyclopedia Database from Broad Institute.


(<http://www.broadinstitute.org/ccle>)

Supplemental Figure 8

A




B




Supplemental Figure 8: Prolonged exposure of KASUMI-1 to I-CBP112 **A:** Cell Cycle phase distribution and **B:** Apoptosis of KASUMI-1 cells analysed by flow cytometry upon treatment with increasing doses of I-CBP112 at different time points. Medium and compound were renewed after 3 days.

Supplemental Figure 9

A




B




Supplemental Figure 9: Prolonged exposure of MOLM13 to I-CBP112. A: Cell Cycle phase distribution and B: Apoptosis of MOLM13 cells analysed by flow cytometry upon treatment with increasing doses of I-CBP112 at different time points. Medium and compound were renewed after 3 days.

Supplemental Figure 10

A




B




Supplemental Figure 10: Prolonged exposure of SEM to I-CBP112. A: Cell Cycle phase distribution and **B:** Apoptosis of SEM cells analysed by flow cytometry upon treatment with increasing doses of I-CBP112 at different time points. Medium and compound were renewed after 3 days.

Supplemental Figure 11




Supplemental Figure 11: Colony formation of 12 human leukemic cell lines upon exposure to I-CBP112. Colony formation of 12 human leukemic cell lines in methylcellulose, exposed to increasing concentrations of I-CBP112.

Supplemental Figure 12



Supplemental Figure 12: Differentiation of CD34⁺ HSCs derived from healthy donors upon exposure to I-CBP112. **A:** CD34⁺ HSCs derived from healthy donors were plated into methylcellulose with increasing concentrations of I-CBP112. Cells were resuspended, spotted on glass slides, Wright- Giemsa stained and morphological changes microscopically analysed. The percentage of differentiated cells was normalized to the total amount counted cells. In total, 20 fields (n) were scored. Shown is the average of differentiation per condition (\pm SD). P- values were calculated using ANOVA and Dunnett multiple comparison, * $p < 0.05$. **B- F:** CD34⁺ derived from healthy donors were plated into methylcellulose with increasing concentrations of I-CBP112. Cells were resuspended and stained with antibodies against CD11b, CD14, CD15, CD34 and CD33 and measured by flow cytometry. Percentages of differentiation were normalized to vehicle- treated cells. Shown is the average of differentiation per condition (\pm SD). P- values were calculated using ANOVA and Dunnett multiple comparison, * $p < 0.05$, n=2.

Supplemental Figure 13

**B**

		JQ-1 1x=0.1uM or 300nM DOXORUBICINE 1x=350nM							
		8:1	4:1	2:1	1:1	1:2	1:4	1:8	1:16
I-CBP 1x=3uM	8x	1x	2x	4x	8x	16x	32x	64x	128x
	4x	0.5x	1x	2x	4x	8x	16x	32x	64x
	2x	0.25x	0.5x	1x	2x	4x	8x	16x	32x
	1x	0.125x	0.25x	0.5x	1x	2x	4x	8x	16x
	0.5x	0.0625x	0.125x	0.25x	0.5x	1x	2x	4x	8x
	0.25x	0.03x	0.0625x	0.125x	0.25x	0.5x	1x	2x	4x
	0.125x	0.016x	0.03x	0.0625x	0.125x	0.25x	0.5x	1x	2x
0.0625x	0.008x	0.016x	0.03x	0.0625x	0.125x	0.25x	0.5x	1x	

C


KASUMI			SEM			MOLM13		
Dose JQ1 (μM)	Dose iCBP112 (μM)	CI	Dose JQ1 (μM)	Dose iCBP112 (μM)	CI	Dose JQ1 (μM)	Dose iCBP112 (μM)	CI
0.0125	0.1875	0.07151	0.025	0.1875	0.03736	0.025	0.75	138229.
0.0125	0.375	0.08530	0.025	0.375	0.04123	0.025	1.5	0.59428
0.0125	0.75	0.11946	0.025	0.75	0.04741	0.025	3.0	0.16364
0.0125	1.5	0.07852	0.025	1.5	0.04710	0.05	0.75	138234.
0.0125	3.0	0.05995	0.025	3.0	0.06295	0.05	1.5	276458.
0.025	0.187	0.10927	0.05	0.1875	0.07162	0.05	3.0	552906.
0.025	0.375	0.13419	0.05	0.375	0.08459	0.1	0.75	0.24331
0.025	0.75	0.13744	0.05	0.75	0.07302	0.1	1.5	0.13580
0.025	1.5	0.14688	0.05	1.5	0.07726	0.1	3.0	0.06637
0.025	3.0	0.12384	0.05	3.0	0.11681	0.2	0.75	0.09736
0.05	0.185	0.13160	0.1	0.1875	0.12969	0.2	1.5	0.21797
0.05	0.375	0.27133	0.1	0.375	0.16130	0.2	3.0	0.07806
0.05	0.75	0.29643	0.1	0.75	0.13019	0.4	0.75	0.07310
0.05	1.5	0.22394	0.1	1.5	0.10142	0.4	1.5	0.12545
0.05	3.0	0.20312	0.1	3.0	0.17312	0.4	3.0	0.13012
			0.2	0.75	0.24473			
			0.2	1.5	0.16754			
			0.2	3.0	0.18006			
			0.4	0.75	0.41170			
			0.4	1.5	0.41068			
			0.4	3.0	0.26769			

D

KASUMI			SEM			MOLM13		
Dose Doxorubicine (nM)	Dose iCBP112 (μM)	CI	Dose Doxorubicine (nM)	Dose iCBP112 (μM)	CI	Dose Doxorubicine (nM)	Dose iCBP112 (μM)	CI
5.6	0.375	0.09798	10.5	0.75	0.27611	10.5	3.0	0.40183
10.5	0.375	0.18102	10.5	3.0	0.55575	21.0	0.75	0.46833
10.5	0.75	0.12549	21.0	0.75	0.96205	21.0	1.5	0.71276
21.0	0.375	0.28315	21.0	1.5	1.59866	21.0	3.0	0.52810
21.0	0.75	0.32060	21.0	3.0	1.41032	44.0	0.75	0.71040
21.0	1.5	0.23050	44.0	0.75	1.30639	44.0	1.5	0.85015
44.0	0.375	0.73736	44.0	1.5	2.87646	44.0	3.0	0.64417
44.0	0.75	0.58487	44.0	3.0	0.57656			
44.0	1.5	0.61536						
44.0	3.0	0.52256						

Supplemental Figure 13: Validation of the synergistic effect in drug combination studies. **A:** Assessment of cytotoxicity of JQ-1, I-CBP112 and Doxorubicin in KASUMI-1, SEM and MOLM13 cells. Cytotoxicity of panBET inhibitor JQ-1, I-CBP112 and Doxorubicin was assessed using WST1 proliferation/survival assays and was plotted as a function of increasing compound concentration. **B:** Schematic showing the set up of the different combinations of I-CBP112 and Doxorubicine or JQ1 used for the treatment of MOLM13, KASUMI-1 and SEM. Tables showing the combination index (CI) upon combination of I-CBP112 and JQ1 (**C:**) or Doxorubicine (**D:**) calculated by the CompuSyn software for KASUMI-1, SEM and MOLM13. Concentrations that gave either no or extreme effect for the single treatment were excluded. CI<1 indicates synergism.

Supplemental Figure 14: Effect of I-CBP112 drug combinations on γ H2Ax



A: SEM, MOLM13 and KASUMI-1 cells were treated with I-CBP112, JQ1, doxorubicine or combination and γ H2Ax (pSer¹³⁹) was assessed by flow cytometry.

B-D: Immunofluorescent staining of γ H2Ax. Representative images for SEM (**B**) MOLM13 (**C**) and KASUMI-1 cells (**D**). Concentrations used for SEM and MOLM13 cells were 1.5 μ M I-CBP112 and 0.4 μ M JQ1 or both and 3 μ M I-CBP112 and 44nM doxorubicine or both. For KASUMI-1, concentrations used were 0.187 μ M I-CBP112 and 12.5nM JQ1 or both and 3 μ M I-CBP and 44nM doxorubicine or both. Bar: 10 μ m

Supplemental Table 7: Significantly regulated genes by exposure to I-CBP112 in KASUMI-1 cells after a 4 day exposure.

SYMBOL	ACCESSION	logFC
RNASE2	NM_002934.2	-1.877835933
FCGR1B	NM_001017986.1	-1.702248652
TNFSF13B	NM_006573.3	-1.67989315
SLC2A5	NM_003039.1	-1.672716922
ANKRD22	NM_144590.2	-1.627742908
TNFSF13B	NM_006573.3	-1.602234026
TRH	NM_007117.1	-1.427931544
DHRS9	NM_005771.3	-1.417342182
RN7SK	NR_001445.1	1.401097459
FCGR1A	NM_000566.2	-1.400344501
ANKRD22	NM_144590.1	-1.36621096
HIST1H2BD	NM_138720.1	1.329553007
CTSG	NM_001911.2	-1.30647185
TP53INP1	NM_033285.2	1.292337987
TP53INP1	NM_033285.2	1.284178791
PDE4B	NM_002600.3	-1.275221813
	BU521176	1.266766603
SLC18A2	NM_003054.2	-1.226578349
GAL	NM_015973.3	-1.193818971
P2RY13	NM_023914.2	-1.187211052
LILRA2	NM_006866.1	-1.177311285
CLEC5A	NM_013252.2	-1.164826148
TGM5	NM_004245.2	-1.150686072
PRIC285	NM_033405.2	1.147669149
RNASE3	NM_002935.2	-1.13822367
CA2	NM_000067.1	-1.116445878
RNU1G2	NR_004426.1	1.111258156
IRF8	NM_002163.2	-1.108626173
LOC100008588	NR_003286.1	1.102030627
CFC1B	NM_001079530.1	-1.098726204
FCGR1B	NM_001004340.1	-1.079403736
SLC22A4	NM_003059.2	-1.078694844
IL8	NM_000584.2	-1.07207046
LOC643332	XR_016287.1	-1.065588146
TCTEX1D1	NM_152665.1	-1.063047603
ARHGAP5	NM_001173.2	-1.057545115
RNU1A3	NR_004430.1	1.045536953
LCP1	NM_002298.2	-1.039447122
CLECL1	NM_172004.2	-1.033544741
LOC100008589	NR_003287.1	1.03060784
TCEA3	NM_003196.1	-1.025015506

SLC44A2	NM_020428.2	1.023368002
KIAA1666	XM_942124.2	1.022623989
RNU1-3	NR_004408.1	1.02212079
GATS	NM_178831.4	1.01158528
RN7SK	NR_001445.1	1.010060857
IGFBP7	NM_001553.1	-1.007405198
ITM2A	NM_004867.3	1.003967171
LMNA	NM_005572.3	0.996687984
ABTB1	NM_032548.2	0.986131497
MXD4	NM_006454.2	0.980475523
RNU1-5	NR_004400.1	0.977493995
SERPINA1	NM_001002236.1	-0.976151167
IL11RA	NM_004512.3	0.975740714
VSIG4	NM_007268.2	-0.965293232
DNAH10	NM_001083900.1	-0.956736082
ID2	NM_002166.4	0.945885703
LOC730517	XM_001126166.1	-0.94501104
ALOX5	XM_001127464.1	0.927333724
ID2	NM_002166.4	0.926328665
NPTX1	NM_002522.2	-0.9251063
CUGBP2	NM_001025076.2	0.923891112
LOC100132394	XM_001713809.1	0.92349068
KLHL24	NM_017644.3	0.923149838
CCL5	NM_002985.2	-0.920773455
NCRNA00085	NR_024330.1	0.91845852
FCGR1C	NM_001128589.1	-0.916015504
LPP	NM_005578.2	0.913557764
TGM5	NM_201631.2	-0.911908708
CCDC92	NM_025140.1	0.911353818
SIGLEC12	NM_053003.2	-0.910665443
PLAC8	NM_016619.1	-0.909829172
ADCY6	NM_020983.2	0.909384648
P2RY13	NM_176894.1	-0.909315511
PLAC8	NM_016619.1	-0.908090985
LOC100133565	XM_001724542.1	0.905216492
KIF1A	NM_004321.4	-0.900979672
LOC100132564	XM_001713808.1	0.893565916
PTRF	NM_012232.3	0.892204925
SERPINA1	NM_001002235.1	-0.888617683
YPEL5	NM_016061.1	0.886604293
MLKL	XM_001126647.1	-0.885082105
LOC727877	XM_001126181.1	0.883305271
CCL5	NM_002985.2	-0.879878746
PRSSL1	NM_214710.2	-0.875868217
RNU4-2	NR_003137.2	0.874835085

SMPDL3B	NM_014474.2	-0.872676098
TM7SF2	NM_003273.2	0.86554732
KIAA1370	NM_019600.2	0.862331804
NINJ2	NM_016533.4	-0.855603147
TMEM71	NM_144649.1	0.855409203
RGL4	NM_153615.1	-0.854372522
TESK2	NM_007170.2	0.853568261
RASSF2	NM_170773.1	0.8534815
NCOA3	NM_181659.1	0.849884433
LOC100008589	NR_003287.1	0.848939478
INSIG1	NM_198336.1	-0.848246145
DLK1	NM_003836.4	-0.846431063
HIST1H2AC	NM_003512.3	0.843040423
CA2	NM_000067.1	-0.841206782
SECISBP2L	NM_014701.2	0.837905551
	CA841942	0.834963108
RPS6KA2	NM_001006932.1	0.833074165
LGALS12	NM_033101.2	-0.831446232
SRGN	NM_002727.2	-0.830685962
RNU6-1	NR_004394.1	0.829563839
STMN3	NM_015894.2	0.829339729
C1orf63	NM_020317.3	0.828028355
FTHL12	NR_002205.1	0.825968874
CCNG2	NM_004354.1	0.824977259
CYTH2	NM_017457.4	0.824749723
SMPDL3B	NM_014474.2	-0.823444679
SAT2	NM_133491.2	0.822114216
ZFP36L1	NM_004926.2	0.820692762
LOC441763	XM_930284.1	0.819514952
KRCC1	NM_016618.1	0.818167224
CHST4	NM_005769.1	-0.81320542
ABCB1	NM_000927.3	0.812903278
STOM	NM_004099.4	-0.811988893
SH3GLB2	NM_020145.2	0.81025036
OCIAD2	NM_001014446.1	0.809796052
MT2A	NM_005953.2	-0.808054071
FTHL16	XR_041433.1	0.805749392
NCOA7	NM_181782.2	-0.805381486
ALOX5AP	NM_001629.2	-0.80425683
ITM2C	NM_001012516.1	0.800105429
LBR	NM_002296.2	-0.798207513
FTHL8	NR_002203.1	0.794555377
RNU6-15	NR_028372.1	0.794393014
DHRS9	NM_005771.3	-0.793265337
NCF2	NM_000433.2	-0.791115019

ITM2C	NM_001012516.1	0.790243251
VSTM1	NM_198481.3	-0.788502886
NFE2	NM_006163.1	-0.78583396
KIAA1370	NM_019600.1	0.783799882
CD247	NM_000734.2	-0.783573864
DRAM1	NM_018370.2	-0.780332899
TRPT1	NM_031472.2	0.780034716
LAMA5	NM_005560.3	0.77978001
SLC22A4	NM_003059.2	-0.778123798
	U62823	0.777208339
CEACAM6	NM_002483.3	-0.776121412
LAX1	NM_017773.2	-0.77448784
CAPN5	NM_004055.4	0.77336783
GAPT	NM_152687.2	-0.772746224
	AK092638	0.772226064
EMR2	NM_152916.1	0.770953593
CCM2	NM_001029835.1	0.76700636
LOC338758	XM_931359.2	0.766703959
LOC100134364	XM_001713810.1	0.766591561
BMF	NM_033503.3	0.764226844
	BC035116	0.762094469
TP53I3	NM_147184.1	0.760896032
SLC22A18	NM_002555.3	0.76042985
CSF3R	NM_172313.1	-0.759201113
SESN1	NM_014454.1	0.756629772
ITGA3	NM_002204.1	0.755436013
FTHL11	NR_002204.1	0.755052893
ST3GAL6	NM_006100.2	-0.753690727
RET	NM_020975.4	-0.752906428
GPR84	NM_020370.1	-0.752814282
KIAA0913	NM_015037.2	0.750458835
EAF2	NM_018456.4	-0.74608937
AGTRAP	NM_001040196.1	-0.745490903
PIK3IP1	NM_052880.3	0.744644082
HBP1	NM_012257.3	0.744163883
FAM116B	NM_001001794.2	0.740225594
KIAA1683	NM_025249.1	0.738507873
ID3	NM_002167.2	0.737841726
ECHDC2	NM_018281.2	0.73715926
POLR3G	NM_006467.2	-0.735486629
LOC730517	XM_001715215.1	-0.732031558
HLA-DMA	NM_006120.2	0.731783475
SHISA2	NM_001007538.1	-0.731193571
CCM2	NM_001029835.1	0.730566218
IRF7	NM_004029.2	0.73052072

MERTK	NM_006343.2	0.730178672
CCNG1	NM_199246.1	0.730060899
	AK055652	0.7274365
AIF1	NM_032955.1	-0.726402363
NDRG1	NM_006096.2	0.724979086
C1orf63	NM_207035.1	0.724226792
S100P	NM_005980.2	-0.721819575
CUGBP2	NM_006561.2	0.720962508
SSBP2	NM_012446.2	0.7209271
RGL1	NM_015149.3	0.720319412
	AF131784	0.717526357
NMI	NM_004688.1	-0.716831381
CTSB	NM_001908.3	0.716777886
ECE2	NM_014693.2	-0.715872055
BTG1	NM_001731.1	0.715026787
CD247	NM_198053.1	-0.712791412
LMNA	NM_005572.3	0.712283107
RNU1F1	NR_004402.1	0.709590265
LOC100133999	XM_001716785.1	0.709133489
AMT	NM_000481.2	0.708810348
FTHL7	NR_002202.2	0.705767355
XPOT	NM_007235.3	-0.705013519
IL1RAP	NM_002182.2	-0.704628555
IL1RAP	NM_134470.2	-0.703317255
MGST1	NM_020300.3	-0.701071913
RPS7	NM_001011.3	-0.698490687
RNU6ATAC	NR_023344.1	0.697287569
GSN	NM_198252.2	-0.695932003
PCBP4	NM_020418.2	0.694727061
KLF12	NM_007249.4	0.694174037
CDR2L	NM_014603.1	0.691743337
TIPIN	NM_017858.1	-0.691653487
CFD	NM_001928.2	0.690555215
RFC2	NM_181471.1	-0.689877528
FTHL12	NR_002205.1	0.689573183
MOAP1	NM_022151.4	0.686746952
KIFC2	NM_145754.2	0.685649227
FAM89A	NM_198552.1	0.685606807
XYLT1	NM_022166.3	0.685480593
RET	NM_020630.4	-0.684257621
FTHL2	NR_002200.1	0.682539387
C5orf41	NM_153607.1	0.682279717
LOC729843	XR_016056.1	0.682173146
TMEM48	NM_018087.3	-0.681631469
KIAA0355	NM_014686.3	0.680904277

POLR3G	NM_006467.2	-0.680346596
FAM176B	NM_018166.1	0.680203808
GOLGA8B	NM_001023567.2	0.679706172
SPSB3	NM_080861.3	0.6772486
PDE4B	NM_002600.3	-0.676925141
ATP9A	NM_006045.1	-0.676837733
SYNGR1	NM_004711.3	-0.676686047
OSTalpha	NM_152672.4	-0.675509103
KIAA1602	NM_020941.1	0.675010441
DDAH2	NM_013974.1	0.674953842
TNFAIP8	NM_001077654.1	-0.674662204
IGLL1	NM_020070.2	-0.674187524
LOC100128291	XR_039099.1	-0.673925454
PSCD1	NM_017456.1	0.672916405
BCL6	NM_001706.2	0.670887872
FTHL11	NR_002204.1	0.670263229
TRIM8	NM_030912.2	0.669794276
HSPD1	NM_002156.4	-0.669694607
TRIP13	NM_004237.2	-0.66856334
SLC7A5	NM_003486.5	-0.666822405
ECM1	NM_022664.1	-0.666818915
CEBPE	NM_001805.2	-0.665448617
LOC730167	XM_001726158.1	-0.664750249
MT1G	NM_005950.1	-0.664688101
P2RX1	NM_002558.2	0.663092985
BNIP3L	NM_004331.2	0.66282058
HIST1H2BD	NM_138720.1	0.661919954
AKNA	NM_030767.3	0.659628157
CDO1	NM_001801.2	0.656206461
PRKDC	NM_006904.6	-0.65620356
CDKN2C	NM_078626.2	0.655944952
RRAS	NM_006270.3	0.655916007
CYTH1	NM_017456.2	0.655539202
	BX097705	-0.655389778
MRPL35	NM_145644.1	-0.653997665
TXNIP	NM_006472.2	0.653424334
GHDC	NM_032484.3	0.653006313
CORO1B	NM_001018070.1	0.652516334
PPP1R15A	NM_014330.2	0.652091186
CTSB	NM_147780.2	0.651905251
UBE1	NM_153280.1	-0.651303867
NTSR1	NM_002531.2	-0.65071254
MLKL	NM_152649.1	-0.650248547
RANBP1	NM_002882.2	-0.649999647
STX5	NM_003164.3	0.649182523

LYAR	NM_017816.1	-0.648106132
CCND3	NM_001760.2	0.647916175
CCDC58	NM_001017928.2	-0.64726471
TTLL3	NM_015644.3	0.644822356
SNORD3D	NR_006882.1	0.644508922
MFSD6	NM_017694.3	0.642543707
LOC100134144	XM_001717999.1	0.642472057
GAPT	NM_152687.2	-0.641792835
LMO2	NM_005574.2	-0.641576633
ADCY6	NM_020983.2	0.641492433
C9orf103	NM_001001551.1	0.639404177
RN5S9	NR_023371.1	0.638596481
HOMER2	NM_199332.2	-0.638269318
SLC25A19	NM_021734.3	-0.6381119
ECM1	NM_004425.2	-0.638015907
DNAJB2	NM_006736.5	0.63765721
AXUD1	NM_033027.2	0.636833989
DBN1	NM_004395.2	0.636620656
TNFRSF6B	NM_032945.2	0.636470315
LOC643870	XM_927140.1	0.63623206
SRGN	NM_002727.2	-0.635497918
LTA4H	NM_000895.1	0.635176309
LAIR2	NM_021270.2	-0.634719989
BIK	NM_001197.3	-0.63449453
RASGRP2	NM_005825.2	-0.633425058
SYT11	NM_152280.2	0.633056298
FAM43A	NM_153690.4	0.632231485
CTDSP2	NM_005730.3	0.631752015
ZNF581	NM_016535.3	0.631005189
CACNB3	NM_000725.2	0.629865677
P2RY5	NM_005767.4	0.629641289
	BX641108	0.628565042
LRRC17	NM_005824.1	-0.628457473
LOC85390	NR_001454.1	-0.628300935
CD68	NM_001251.1	-0.627528383
ZNF211	NM_006385.2	0.627481848
S100A4	NM_019554.2	0.627175686
PPM1G	NM_177983.1	-0.62456829
SC4MOL	NM_006745.3	-0.624455616
MS4A7	NM_206938.1	-0.623637243
PTGER2	NM_000956.2	-0.622068997
TUG1	NR_002323.1	0.621592305
TSPAN9	NM_006675.3	0.620161447
C2orf65	NM_138804.3	-0.619464591
ICAM3	NM_002162.2	0.61939787

PTMS	NM_002824.4	0.619301501
ZMIZ1	NM_020338.2	0.618878221
MLKL	XM_001126647.1	-0.61866213
MYO1G	NM_033054.1	0.617504858
FAM89A	XM_939093.1	0.617246513
GART	NM_175085.1	-0.61661938
HOMER2	NM_199331.2	-0.616447403
MNDA	NM_002432.1	-0.616388269
MGEA5	NM_012215.2	0.615816839
LRMP	NM_006152.2	-0.615757849
ASMTL	XM_942506.1	0.614244868
MTSS1	NM_014751.4	0.613367328
PHF17	NM_024900.3	-0.613235638
TUFT1	NM_020127.1	0.612393134
NFKBIE	NM_004556.2	-0.61212368
RHOC	NM_175744.4	0.611937489
RCOR3	NM_018254.2	0.610821781
ASS1	NM_000050.4	-0.609848981
TGFBR2	NM_001024847.2	0.609692395
BRI3BP	NM_080626.5	-0.609568246
PDE4D	NM_006203.3	-0.609471243
ANKDD1A	NM_182703.3	0.608932951
LRCH4	NM_002319.2	0.608665413
INSIG1	NM_198336.1	-0.608446056
CNFN	NM_032488.2	0.607397975
BRI3BP	NM_080626.5	-0.606384615
ATP5G1	NM_005175.2	-0.606358576
LOC728047	XM_001126912.1	-0.606015376
ARSD	NM_001669.2	0.605826016
MFSD6	NM_017694.3	0.604045483
RPL37	NM_000997.3	0.604005073
CDC25A	NM_001789.2	-0.603948054
SHANK3	NM_001080420.1	0.603667952
LOC727761	XM_001126211.1	-0.603332553
MMP28	NM_001032278.1	0.603221248
GATA2	NM_032638.3	0.60315307
ELOVL6	NM_024090.1	-0.601851932
CROP	NM_016424.3	0.601134848
LOC791120	NR_015357.1	0.601015752
SLC38A5	NM_033518.1	-0.600923909
BAZ2B	NM_013450.2	0.600864634
LYAR	NM_017816.1	-0.600640929
PHACTR1	NM_030948.1	-0.599881581
NMB	NM_021077.3	-0.599807393
PKD2	NM_000297.2	0.599096317

TOR3A	NM_022371.3	-0.598939175
RNU4-1	NR_003925.1	0.598803729
LOC100130892	XM_001720172.1	0.598800657
LRRC17	NM_001031692.1	-0.598235129
LOC653344	XM_933085.1	0.598008851
ABCB1	NM_000927.3	0.597637727
TSPYL3	XR_001421.1	0.597611318
FAM89B	NM_001098784.1	0.597217488
	AK092074	0.597188448
CEBPD	NM_005195.3	-0.596688203
TPRG1L	NM_182752.3	0.596467979
NPC2	NM_006432.3	0.59639002
LGSN	NM_016571.1	0.596251234
LOC644914	XM_930111.2	0.59622382
ERO1L	NM_014584.1	-0.595578478
CCDC24	NM_152499.1	0.595513371
PRIM2A	XM_001134299.1	-0.594758774
NCRNA00219	NR_015370.1	0.594001793
HCST	NM_001007469.1	0.593612238
LPIN1	NM_145693.1	0.593567028
BHLHB2	NM_003670.1	0.59334335
ZWILCH	NM_017975.3	-0.592021701
RRS1	NM_015169.3	-0.591416436
ZNF326	NM_182976.1	-0.591339579
C5orf41	NM_153607.1	0.590530783
LOC644162	XM_933956.1	-0.590046944
LSM12	NM_152344.2	-0.58963917
GTF2H3	NM_001516.3	-0.588718397
C14orf179	NM_052873.1	0.587394635
COL4A5	NM_000495.3	0.587210266
OSBPL2	NM_144498.1	0.586381288
CAST	NM_001042442.1	0.586223935
B3GNTL1	NM_001009905.1	-0.586183713
SLC38A10	NM_138570.2	-0.586011882

Supplemental Table 8: Significantly regulated genes by exposure to I-CBP112 in MOLM13 cells after a 4 day exposure.

SYMBOL	ACCESSION	logFC
PRG2	NM_002728.4	-1.639232194
MS4A3	NM_006138.4	-1.47321975
IL8	NM_000584.2	-1.396195453
CACNA2D3	NM_018398.2	-1.344117221
MPO	NM_000250.1	-1.327633118
MS4A3	NM_006138.4	-1.297766477
AIF1	NM_032955.1	-1.295411069
CST7	NM_003650.2	-1.285628397
RNASE3	NM_002935.2	-1.262303279
CTSG	NM_001911.2	-1.261036568
CHI3L1	NM_001276.2	-1.217610872
SERPINB10	NM_005024.1	-1.131353157
CUX2	NM_015267.2	-1.118701772
NFE2	NM_006163.1	-1.109079544
LOC643332	XR_016287.1	-1.09412978
FCGR1A	NM_000566.2	-1.089914598
RNASE2	NM_002934.2	-1.074627798
C5orf20	NM_130848.2	-1.032472915
EGR1	NM_001964.2	1.011502202
MS4A6A	NM_152851.1	-1.002900864
RGS18	NM_130782.2	-1.002391126
S100A8	NM_002964.3	-1.001889746
AIF1	NM_001623.3	-0.993513043
S100A9	NM_002965.2	-0.972289041
CFC1B	NM_001079530.1	-0.957997689
FGR	NM_001042729.1	-0.955300402
IL8	NM_000584.2	-0.949369292
C19orf59	NM_174918.2	-0.946978511
SPNS3	NM_182538.3	-0.944210941
CCR2	NM_000647.3	-0.941974527
LOC730517	XM_001126166.1	-0.938078431
CORO2A	NM_003389.2	-0.927753323
SNORA12	NR_002954.1	0.923431985
PRSSL1	NM_214710.2	-0.90604267
ARHGAP5	NM_001173.2	-0.885604357
MS4A6A	NM_022349.2	-0.866908432
CD36	NM_000072.2	-0.853740183
ORM1	NM_000607.1	-0.853486456
LILRA2	NM_006866.1	-0.849052167
RAB7B	NM_177403.3	-0.848573119
CCR2	NM_000647.4	-0.84591215

CSF3R	NM_172313.1	-0.84467196
SERPINB2	NM_002575.1	-0.833119858
PECAM1	NM_000442.3	-0.831750476
SERPINB2	NM_002575.1	-0.830261994
MLC1	NM_015166.3	-0.829717972
FCGR1B	NM_001017986.1	-0.824932499
BPI	NM_001725.1	-0.824047912
CCL3L1	NM_021006.4	-0.82157174
CD52	NM_001803.2	-0.813481394
TNFSF13B	NM_006573.3	-0.812783834
THBS4	NM_003248.3	-0.810154773
HLA-DRA	NM_019111.3	-0.792283023
SCARNA14	NR_004388.1	0.778835793
MNDA	NM_002432.1	-0.778103696
TIFAB	NM_001099221.1	-0.769664747
CCR2	NM_000648.2	-0.769503313
TSPAN32	NM_005705.4	-0.768712406
SERPINB8	NM_002640.3	-0.767695904
FCGR1B	NM_001004340.1	-0.753559572
MS4A4A	NM_148975.1	-0.752748701
ASMTL	XM_942506.1	0.747425804
SCARNA13	NR_003002.1	0.746507053
RN5S9	NR_023371.1	0.742090357
CXCR4	NM_001008540.1	-0.740410413
FCER2	NM_002002.3	-0.724726185
IFI6	NM_022873.2	0.721309592
ARHGEF10	NM_014629.2	-0.719462384
LST1	NM_007161.2	-0.717548735
CPVL	NM_019029.2	0.714203485
TBC1D10C	NM_198517.2	-0.711969457
C13orf18	NM_025113.1	-0.707352932
SNORD31	NR_002560.1	0.705285853
TMEM45A	NM_018004.1	-0.704596247
TRAPPC6A	NM_024108.1	0.703279731
CSPG4	NM_001897.4	-0.701991311
PRDM8	NM_020226.3	-0.699029818
TGM5	NM_004245.2	-0.696730621
CD36	NM_001001548.1	-0.694044215
S1PR3	NM_005226.2	-0.685589366
FCGR1C	NM_001128589.1	-0.675616436
CYFIP2	NM_014376.2	0.671141626
ATP6V1C2	NM_144583.3	-0.669259049
TMEM14A	NM_014051.3	0.667309603
MS4A6A	NM_152851.1	-0.663502021
PNOC	NM_006228.3	-0.663144916

SNORA57	NR_004390.1	0.660109179
GPR18	NM_001098200.1	-0.659289432
LY96	NM_015364.2	0.658397331
RARRES3	NM_004585.3	0.656919611
IDI1	NM_004508.2	-0.656310383
	AY129027	-0.6537868
37134	NM_002688.4	-0.650478319
DHRS9	NM_005771.3	-0.645904872
FTHL7	NR_002202.2	0.645039294
	BX093329	-0.638482928
PTPN22	NM_015967.3	-0.638457746
NANOS1	NM_001009553.1	-0.636033874
SNX10	NM_013322.2	-0.635840359
DYSF	NM_003494.2	-0.635214108
SCARNA8	NR_003009.1	0.635192062
SYTL1	NM_032872.1	-0.628275589
PSAP	NM_001042465.1	0.626516856
BASP1	NM_006317.3	-0.624755931
LOC100134379	XM_001720508.1	-0.623016327
TGM5	NM_201631.2	-0.621688195
SERPINB8	NM_198833.1	-0.621530316
CLCF1	NM_013246.2	-0.616351318
TNFSF13B	NM_006573.3	-0.615822026
FCER1G	NM_004106.1	-0.613515389
RASGRP2	NM_005825.2	-0.612685259
PLAC8	NM_016619.1	-0.612598797
C13orf18	NM_025113.1	-0.611826776
GPR84	NM_020370.1	-0.610399762
LOC100134648	XM_001724681.1	0.608430501
SQRDL	NM_021199.2	-0.606590774
SLC22A4	NM_003059.2	-0.606522551
IGLL1	NM_020070.2	-0.606142732
MLKL	NM_152649.1	-0.605608678
WNT7B	NM_058238.1	-0.605008071
PSTPIP1	NM_003978.2	-0.604192959
CCL3L3	NM_001001437.3	-0.595676743
SHISA2	NM_001007538.1	-0.59528192
METTL7B	NM_152637.1	-0.594434951
C3orf54	NM_203370.1	-0.591699864
CAT	NM_001752.2	-0.589083482
INSIG1	NM_198336.1	-0.586611857
CHST13	NM_152889.1	-0.586012155
PLD3	NM_001031696.1	0.585269752

Supplemental Table 9: Significantly regulated genes by exposure to I-CBP112 in SEM cells after a 4 day exposure.

SYMBOL	ACCESSION	logFC
LOC100008589	NR_003287.1	2.444459698
LOC100132394	XM_001713809.1	2.318606627
LOC100008589	NR_003287.1	2.310711627
LOC100134364	XM_001713810.1	2.063037994
LOC100133565	XM_001724542.1	1.990136006
CSF1R	NM_005211.2	-1.985680186
ADAMTSL2	NM_014694.2	1.902519787
LOC441763	XM_930284.1	1.887924452
SLC7A7	NM_003982.2	-1.842173109
ID2	NM_002166.4	1.730565243
ID2	NM_002166.4	1.637947926
MGC33556	NM_001004307.1	-1.63673205
SMAD7	NM_005904.2	1.63331177
VENTX	NM_014468.2	-1.566521159
HSPB7	NM_014424.3	-1.525703903
SNORA12	NR_002954.1	1.519383144
CST7	NM_003650.2	-1.512389163
CSPG4	NM_001897.4	-1.505235008
NFE2	NM_006163.1	-1.471124194
BMF	NM_033503.3	1.432866046
PDGFRB	NM_002609.3	-1.401235528
PRSSL1	NM_214710.2	-1.331933325
TMEM119	NM_181724.1	1.305513996
IL21R	NM_181078.1	-1.299587543
SCD	NM_005063.4	-1.297479005
ADA	NM_000022.2	-1.28400768
ANXA2	NM_001002857.1	-1.279952046
CD72	NM_001782.1	-1.278144098
NELL2	NM_006159.1	1.27783016
MIR1978	NR_031742.1	-1.270179683
SMAD7	NM_005904.2	1.260744223
SCARNA13	NR_003002.1	1.259635487
CD52	NM_001803.2	-1.252455896
ISG20	NM_002201.4	-1.247740807
CYSLTR1	NM_006639.2	-1.245432152
IFITM1	NM_003641.3	-1.232095307
LCN6	NM_198946.2	-1.231159153
SLC43A2	NM_152346.1	1.228705384
C17orf87	NM_207103.1	-1.226024261
LRIG1	NM_015541.2	1.207224498

RGS2	NM_002923.1	-1.206134551
BMF	NM_001003943.1	1.203282656
ECM1	NM_022664.1	-1.192197833
NQO1	NM_000903.2	1.18281644
FOS	NM_005252.2	-1.17586733
BAMBI	NM_012342.2	1.164360057
MXD4	NM_006454.2	1.160080602
ACAD11	NM_032169.4	-1.14365653
HLA-DRB4	NM_021983.4	-1.139998934
EGR1	NM_001964.2	-1.137059502
AK3L1	NM_013410.2	-1.120208128
TLE4	NM_007005.3	1.119221832
LILRA2	NM_006866.1	-1.115064082
CA2	NM_000067.1	-1.108890281
PLEK	NM_002664.1	-1.107076323
CYP1A1	NM_000499.2	1.107044348
PGAM1	NM_002629.2	-1.097093724
LRIG1	NM_015541.2	1.09512074
DAAM1	NM_014992.1	1.093623976
SREBF1	NM_001005291.1	-1.093074921
	AK026966	-1.088680791
GP9	NM_000174.2	-1.087262843
NLGN4X	NM_020742.2	-1.085104953
REEP1	NM_022912.1	1.066683035
C17orf87	NM_207103.2	-1.065368685
CCL5	NM_002985.2	-1.053819584
NPW	NM_001099456.2	-1.052619524
SLC15A3	NM_016582.1	-1.051897951
EVL	NM_016337.2	-1.05121774
NKG7	NM_005601.3	-1.047671857
CTNBL1	NM_030877.3	-1.033308027
FAM69B	XM_001130258.1	-1.033251279
VWA5A	NM_014622.4	1.026270141
SORBS2	NM_003603.4	1.024122526
HSH2D	NM_032855.2	-1.007776123
CHN2	NM_004067.2	1.007047038
LOC728188	XM_001126103.2	-1.004808883
DDN	NM_015086.1	-1.004787523
SNORD13	NR_003041.1	0.99059668
APOBEC3G	NM_021822.1	-0.988783363
CACNA2D4	NM_172364.4	-0.981774933
RFTN1	NM_015150.1	0.981498214
TLE4	NM_007005.3	0.971960662
ARSD	NM_001669.2	0.971143967
ADARB1	NM_001112.2	0.970185563

HOPX	NM_139212.2	0.969015484
LIMS2	NM_017980.3	-0.968395228
RGL1	NM_015149.3	0.965748132
S100A13	NM_001024211.1	-0.96570075
KAZALD1	NM_030929.3	-0.959295913
SLC16A3	NM_004207.2	-0.958353187
CARD9	NM_052813.3	-0.950676565
RUNX2	NM_001024630.2	0.949879104
AK3L1	NM_203464.1	-0.948593208
CTSO	NM_001334.2	0.944958519
LOC387841	XM_932678.1	-0.941383181
ANPEP	NM_001150.1	0.940240348
SLA	NM_006748.1	-0.933212782
MCOLN2	NM_153259.2	-0.92582889
SH3BP4	NM_014521.2	0.922806371
ACACA	NM_198839.1	-0.915553918
CLEC11A	NM_002975.2	-0.912467558
TBC1D10C	NM_198517.2	-0.911651062
ANGPT1	NM_001146.3	-0.908733882
LOC643384	XR_016363.2	-0.906382262
CCDC81	NM_021827.3	-0.905115396
SPIRE1	NM_020148.2	0.900306925
CYTH1	NM_017456.2	0.899583409
SORBS2	NM_003603.4	0.898761626
CTNNA1	NM_001903.2	0.898648128
HNRPLL	NM_138394.2	0.898274719
UNC93B1	NM_030930.2	-0.898201169
CA2	NM_000067.1	-0.89534568
SORD	XM_001132175.1	-0.893251578
ABLIM1	NM_006720.3	0.890419807
MYO10	NM_012334.1	0.889352737
SLC22A16	NM_033125.2	-0.886518474
GPM6B	NM_001001995.1	-0.885789177
CRMP1	NM_001014809.1	0.884390825
EFNB2	NM_004093.2	0.884331445
IRAK2	NM_001570.3	-0.882557916
FADS1	NM_013402.3	-0.881501449
MPPE1	NM_023075.4	0.880816171
CD86	NM_006889.3	-0.880811133
CCL5	NM_002985.2	-0.879251206
C19orf59	NM_174918.2	-0.87427298
ITPRIPL2	NM_001034841.2	-0.870008173
TCF7	NM_213648.1	0.866048729
DHCR7	NM_001360.1	-0.865962211
FAM65B	NM_015864.2	-0.862169363

TCF7	NM_201632.1	0.861658995
GPM6B	NM_001001995.1	-0.861527561
GNB4	NM_021629.2	-0.861055954
PRICKLE1	NM_153026.1	-0.860069071
KCNK3	NM_002246.1	0.85800232
GREM1	NM_013372.5	0.854828333
RPS6KA2	NM_001006932.1	0.854536594
RAPGEF2	NM_014247.2	0.853714263
	AF131834	0.853567135
RN7SK	NR_001445.1	0.850423205
KLHL24	NM_017644.3	0.850310568
CD79B	NM_000626.1	-0.850076641
TPMT	NM_000367.2	0.847480228
PKDCC	NM_138370.2	-0.846514463
TP53INP1	NM_033285.2	0.84550346
NRCAM	NM_005010.3	0.839689695
SYTL2	NM_206929.1	0.838653717
S100A13	NM_001024211.1	-0.83706123
CDKN1A	NM_000389.2	-0.836309224
PSCD1	NM_017456.1	0.834015203
S100A13	NM_001024212.1	-0.832242313
PLAUR	NM_001005376.1	-0.831926161
SNORD12C	NR_002433.1	-0.831206099
FASN	NM_004104.4	-0.830498859
C1orf63	NM_020317.3	0.826372736
CORO1A	NM_007074.2	-0.82591161
LOC649143	XM_944822.1	-0.825680121
HLA-DRB6	NR_001298.1	-0.823764332
FSCN1	NM_003088.2	-0.823182387
CCDC106	NM_013301.2	-0.822315318
CEBPB	NM_005194.2	0.821110697
GNB4	NM_021629.3	-0.819776351
MFI2	NM_033316.2	0.818571438
CD93	NM_012072.3	-0.816159575
EMILIN1	NM_007046.1	-0.813510621
RASGRP3	NM_170672.1	0.811159888
LOC100132564	XM_001713808.1	0.81094413
CHI3L2	NM_004000.2	-0.807882681
MYH9	NM_002473.3	0.807819307
CCND3	NM_001760.2	-0.807598849
MACROD1	NM_014067.2	-0.80702333
HSZFP36	NM_001080493.1	0.806301402
INSIG1	NM_198336.1	-0.805443491
ACACA	NM_198836.1	-0.803813867
DSTN	NM_001011546.1	0.803560296

TMEM158	NM_015444.2	0.802197413
NMT2	NM_004808.1	0.799218365
C17orf60	NM_001085423.1	-0.798368058
PSD2	NM_032289.2	0.796925959
TNFSF13B	NM_006573.3	-0.795673942
INSIG1	NM_198336.1	-0.794985025
RERE	NM_001042682.1	0.792276266
KCNS3	NM_002252.3	0.790742178
ANXA2	NM_001002858.1	-0.789939269
CKAP2	NM_018204.2	0.788627091
C17orf53	NM_024032.2	-0.785977439
DHRS3	NM_004753.4	-0.785922885
RAB8A	NM_005370.4	-0.784060143
CD79B	NM_001039933.1	-0.781067398
MLL5	NM_018682.3	0.77969212
IFITM2	NM_006435.2	-0.77933967
TP53INP1	NM_033285.2	0.775735014
ORC6L	NM_014321.2	-0.775294049
DHCR7	NM_001360.2	-0.774882646
NME1	NM_000269.2	-0.77414241
ARHGEF3	NM_019555.1	0.773258218
CRIP2	NM_001312.2	0.772792745
PLAUR	NM_001005376.1	-0.772070605
BATF3	NM_018664.1	-0.771561379
XYLT1	NM_022166.3	0.768200247
SLAMF1	NM_003037.1	0.768193908
CCNA1	NM_003914.2	-0.765017913
LOC730415	XM_001720835.1	-0.764130725
WDR19	NM_025132.3	0.763971117
BASP1	NM_006317.3	0.762283331
C7orf41	NM_152793.2	0.762046698
NLGN4X	NM_020742.2	-0.760206794
TSC22D1	NM_006022.2	0.760161323
ARHGAP30	NM_181720.2	-0.758455574
ORC1L	NM_004153.2	-0.753760954
SNORA64	NR_002326.1	-0.751872187
SRGN	NM_002727.2	-0.751278386
RALGAPA1	NM_194301.2	0.749416514
PACS1	NM_018026.2	0.748461229
ABCB6	NM_005689.1	0.74727924
RASD2	NM_014310.3	-0.746399733
AKR1C3	NM_003739.4	0.745651589
P2RY11	NM_002566.4	-0.745464666
DPAGT1	NM_001382.2	-0.744598043
PELI2	NM_021255.2	0.744449396

TAGLN2	NM_003564.1	-0.7425604
THOC4	NM_005782.2	-0.742357178
ABHD4	NM_022060.2	-0.741618223
GNA15	NM_002068.1	-0.741519715
LOC653994	XM_944429.1	-0.740046121
LONRF1	NM_152271.3	-0.739563349
DNAJB2	NM_006736.5	0.73891344
LOC283340	XM_932919.1	-0.73719782
	AK091337	0.736178708
MT1F	NM_005949.2	0.734524054
SPI1	NM_001080547.1	-0.733382841
PRPH	NM_006262.3	0.73233737
PTPN7	NM_080588.1	-0.732276344
GABARAPL1	NM_031412.2	0.731455528
TMEM184B	NM_012264.3	0.730626486
AIF1	NM_032955.1	-0.727723146
FOXO3	NM_201559.2	0.727459876
SPSB1	NM_025106.2	0.727249395
	CR592039	-0.726340753
FAM81A	NM_152450.2	-0.726234273
MYO6	NM_004999.3	0.725608325
PER3	NM_016831.1	-0.725275464
SLC27A3	NM_024330.1	-0.724281449
ARHGEF7	NM_003899.2	0.722758858
PLAC8	NM_016619.1	-0.722430732
DAAM1	NM_014992.1	0.720986722
ATP6V0B	NM_001039457.1	-0.720863614
MIR1228	NR_031597.1	-0.71991893
N4BP2	NM_018177.2	0.717874259
WASPIP	NM_003387.3	-0.716850411
PLXDC2	NM_032812.7	-0.715873849
CD9	NM_001769.2	-0.713654668
FAM89B	NM_001098784.1	0.71349931
SREBF1	NM_004176.3	-0.713134511
FADS2	NM_004265.2	-0.712844496
CCDC46	NM_145036.2	0.712773073
ICAM2	NM_001099786.1	-0.712426759
PFN2	NM_053024.2	0.711844445
ANGPTL2	NM_012098.2	-0.709989181
TNFSF13B	NM_006573.3	-0.709680205
CHES1	NM_005197.2	0.709176554
FTHL12	NR_002205.1	0.708816999
DTNA	NM_001392.3	-0.708414524
MCM7	NM_005916.3	-0.707842881
FGFBP2	NM_031950.2	0.707193716

EP400	NM_015409.3	0.705403807
SPEN	NM_015001.2	0.704464632
SLC44A1	NM_080546.3	0.704169385
PLEKHA1	NM_001001974.1	0.703853535
WIPI1	NM_017983.4	0.703416801
SNORA84	NR_003704.2	-0.702967194
HLA-DRB6	NR_001298.1	-0.702334473
IRF8	NM_002163.2	-0.701635165
LPAR5	NM_020400.4	-0.700983852
RERE	NM_012102.3	0.699629987
MEGF6	NM_001409.3	-0.699164069
NR4A2	NM_006186.2	0.698587739
DKFZp761P0423	XM_291277.4	-0.697975731
APOBEC3G	NM_021822.1	-0.696939404
CYTSA	NM_015330.1	0.696089763
ABR	NM_001092.3	0.695731865
BIRC2	NM_001166.3	0.694728775
ANXA2P1	NR_001562.1	-0.694703887
LOC606724	NR_002454.2	-0.694394455
SNX7	NM_152238.1	0.693747011
S100A4	NM_019554.2	-0.693102104
LOC100130458	XM_001716901.1	0.691620303
RN7SK	NR_001445.1	0.690301409
IKZF1	NM_006060.3	-0.689947242
ACSL1	NM_001995.2	0.689773956
PGAM1	NM_002629.2	-0.688517646
	BC070337	-0.685450515
KIAA1267	NM_015443.2	0.685421104
MRPL33	NM_145330.2	-0.685155012
SLC44A1	NM_080546.3	0.682603348
HSPC111	NM_016391.3	-0.68231748
NBPF20	NM_001037675.1	0.681704163
LOC200030	NM_183372.3	0.681457263
UGT3A2	NM_174914.2	-0.681293839
PPM1M	NM_144641.1	-0.681267452
SNORA6	NR_002325.1	-0.680799166
MYRIP	NM_015460.2	0.680797942
UHRF1	NM_013282.3	-0.680666563
SC4MOL	NM_001017369.1	-0.679834498
UPP1	NM_003364.2	0.679441135
C1orf63	NM_207035.1	0.679172853
PRAGMIN	NM_001080826.1	-0.678817544
KCNN4	NM_002250.2	-0.678465652
FCRLA	NM_032738.3	-0.678355953
LY86	NM_004271.3	-0.678141134


BCOR	NM_017745.4	0.677505994
NOP16	NM_016391.4	-0.676470351
GRAMD4	NM_015124.2	-0.675770436
TSC22D1	NM_006022.2	0.675406222
SLC7A3	NM_032803.4	0.674809903
NRCAM	NM_005010.3	0.674104604
SC4MOL	NM_006745.3	-0.672643926
SLITRK4	NM_173078.2	-0.672543813
GREM1	NM_013372.5	0.672368369
LOC732007	XR_015684.1	-0.672357074
IL1RN	NM_173843.1	-0.672179882
CRLF2	XM_001133960.1	-0.671181222
KCNMB1	NM_004137.2	-0.66862687
C11orf67	NM_024684.2	0.668543353
RPL8	NM_033301.1	-0.668538471
FBXO32	NM_148177.1	0.666753111
CSRP2	NM_001321.1	0.665099304
RPL13	NM_033251.1	-0.664996087
BTG2	NM_006763.2	0.663564702
NPAL3	NM_020448.3	0.663548569
ZNF232	NM_014519.2	-0.662934829
SNORD36C	NR_000016.1	-0.661906138
MRPL33	NM_004891.2	-0.661887392
RYBP	NM_012234.4	0.661408682
CD33	NM_001772.3	-0.660964461
CD70	NM_001252.3	-0.660833443
THOC4	XM_001134346.1	-0.660795321
CTNNA1	NM_001903.2	0.660382476
ZNF443	NM_005815.2	0.660298437
AFMID	NM_001010982.2	-0.659539886
ATP2A3	NM_174955.1	0.659244172
MPRIP	NM_015134.2	0.658742528
OPTN	NM_001008213.1	0.65841584
WASF3	NM_006646.4	0.657175649
PPP2R5C	NM_002719.2	-0.65687046
NMT2	NM_004808.2	0.656717521
ADORA2B	NM_000676.2	-0.65594592
SNORD31	NR_002560.1	-0.655228044
ZNF627	NM_145295.2	0.654253431
BCOR	NM_020926.2	0.653166196
TRO	NM_001039705.1	0.652965423
SLC24A6	NM_024959.2	0.652627683
LOC644063	XR_016547.1	-0.652535845
FAM113B	NM_138371.1	-0.649967636
ANKRD41	NM_152363.2	-0.649857101

RALGPS1	NM_014636.1	0.649695753
PNKD	NM_022572.2	-0.649414801
ARHGAP30	NM_001025598.1	-0.649255942
GARNL4	NM_015085.3	-0.64848921
PSMC4	NM_006503.2	-0.6479817
KLRC3	NM_002261.2	0.64701401
LOC284422	XM_209196.5	-0.646875501
ALDH3B1	NM_000694.2	-0.646530138
LOC646786	XM_929738.1	0.646084199
MLKL	NM_152649.1	-0.645118512
NPHP3	NM_153240.3	0.645039308
CXXC5	NM_016463.7	0.644395259
RFXANK	NM_134440.1	-0.642224833
WDR74	XM_001125771.1	-0.642045054
SLA	NM_001045557.1	-0.641383126
FAIM3	NM_005449.3	-0.641012722
CHN2	NM_004067.2	0.640984355
UNC93B1	NM_030930.2	-0.640806438
CIDEB	NM_014430.2	-0.640771253
LIN28B	NM_001004317.2	-0.640636269
ZNF84	NM_003428.4	0.639943429
BDH1	NM_203314.2	-0.639367962
SLC17A9	NM_022082.3	-0.638944344
BHLHB2	NM_003670.1	0.637554076
SFXN4	NM_213650.1	-0.636624224
LOC91461	NM_138370.1	-0.636305323
ADD1	NM_001119.3	0.636170683
CD99	NM_002414.3	0.635133593
WDR12	NM_018256.2	-0.634143054
SPTAN1	NM_003127.1	0.633805715
RN5S9	NR_023371.1	0.63237276
TESK2	NM_007170.2	0.6322145
SNORA45	NR_002977.1	-0.631567028
GATM	NM_001482.2	-0.631159587
DHCR24	NM_014762.3	-0.630778043
PKD2	NM_000297.2	0.630322351
LOC100133163	XM_001726385.1	0.629845066
ACBD7	XM_928013.1	0.62967076
MAZ	NM_001042539.1	0.629612286
TEAD4	NM_201443.1	-0.628645045
RNF125	NM_017831.3	-0.628633249
LOC643446	XM_001131589.1	-0.6284174
XAF1	NM_199139.1	-0.627507825
CRBN	NM_016302.2	0.627302686
TRO	NM_001039705.1	0.627277535

STMN3	NM_015894.2	0.627136233
RTN4R	NM_023004.5	-0.625796205
ZSWIM6	XM_035299.8	0.624776878
MAPK13	NM_002754.3	-0.624688488
LOC642755	XM_926382.2	0.622726918
HMGCS1	NM_002130.6	-0.622305774
38595	NM_006640.3	0.621840242
RASSF1	NM_170712.1	-0.620625957
ITGB2	NM_000211.1	-0.620385442
SLC26A9	NM_052934.2	-0.619343218
ULK1	NM_003565.1	0.618800676
LACTB	NM_032857.2	0.618271457
S100A4	NM_019554.2	-0.61813018
C6orf185	XM_168055.6	-0.618095485
ZNF296	NM_145288.1	-0.617960852
ALDOC	NM_005165.2	-0.617390503
ACVR1	NM_001105.2	0.61715559
ULK1	NM_003565.1	0.616869259
PLEKHA1	NM_021622.3	0.61686098
SRGN	NM_002727.2	-0.616781535
FLJ20021	XM_028217.4	0.616513635
PHLDA1	NM_007350.3	0.616480507
TMEM91	NM_001042595.1	0.616312108
UBL3	NM_007106.2	0.615953795
TRPM2	NM_001001188.3	-0.615708759
LOC401152	NM_001001701.1	0.615024343
LOC651697	XR_039237.1	-0.61461379
ARHGAP9	NM_001080156.1	-0.614417583
GCLC	NM_001498.2	0.61415459
	AW967735	-0.613868384
PDCD6IP	NM_013374.3	0.613377252
CST3	NM_000099.2	0.61197513
AK3L1	NM_203464.1	-0.611936431
APOBEC3B	NM_004900.3	-0.611789771
TLR10	NM_001017388.1	-0.610641386
CAST	NM_001042442.1	0.609957429
ZNF823	NM_001080493.2	0.608611175
COMTD1	NM_144589.2	-0.608323553
FYN	NM_153047.1	0.608228747
LOC401233	NM_001013680.1	0.607740554
YPEL5	NM_016061.1	0.606964344
TBC1D8B	NM_198881.1	-0.606928041
ZNF232	NM_014519.2	-0.606378267
MOAP1	NM_022151.4	0.605427504
ABLIM1	NM_001003407.1	0.605036661


STAMBPL1	NM_020799.2	-0.604874337
CXXC5	NM_016463.5	0.604256568
CD79A	NM_001783.3	-0.603661787
CECR1	NM_177405.1	0.603017303
	BC035116	0.602337079
TSEN34	NM_001077446.1	0.601990962
FNBP1	NM_015033.2	0.601625635
BAZ2B	NM_013450.2	0.600526755
ITPKA	NM_002220.1	-0.598355197
FTHL2	NR_002200.1	0.598093312
TMEM135	NM_022918.2	-0.596435772
RASSF1	NM_007182.4	-0.595928474
GBF1	NM_004193.1	0.595736805
DKFZp451A211	NM_001003399.1	-0.595537191
LOC653994	XM_944439.2	-0.594321004
SMG7	NM_173156.1	0.594065009
PFKFB3	NM_004566.2	0.59329284
RPL34	NM_033625.2	-0.593059328
INPP5D	NM_005541.3	-0.592531692
SULT1A1	NM_177536.1	-0.592004332
DNAJC12	NM_021800.2	-0.591627104
AKAP13	NM_007200.3	0.591541714
SLC13A5	NM_177550.2	-0.591283368
CTSK	NM_000396.2	0.591155904
DACT3	NM_145056.1	0.591148876
DNAJC12	NM_201262.1	-0.591050343
SPG11	NM_025137.3	0.590916844
KIF7	NM_198525.1	0.589781842
DUSP18	NM_152511.3	0.589514735
FAM101B	NM_182705.2	-0.589219517
GLIPR2	NM_022343.2	0.589119895
DAZAP1	NM_170711.1	-0.588276915
NLRP3	NM_004895.3	-0.587847422
NP	NM_000270.1	-0.587826014
ATF4	NM_001675.2	-0.587796083
LDLR	NM_000527.2	-0.586050414
BTBD11	NM_152322.2	0.585595313

Supplemental Figure 15:



Supplemental Figure 15. Expression changes of selected cell cycle regulator target genes on mRNA level in KASUMI-1 cells upon exposure of I-CBP112: Expression changes of selected cell cycle target genes on mRNA level, measured by q-RTPCR, in KASUMI-1 cells upon exposure of I-CBP112 (3 μ M) for 8 hours, 1 and 4 days. Ct were first normalized to GAPDH housekeeping gene and then to the average of vehicle- treated (DMSO) cells (Relative expression=1). P- values were calculated using a two- way ANOVA test and Turkey multiple comparison: ns= not significant, * p<0.05 ** p<0.01 *** p<0.001 **** p<0.0001, n=2.

Supplemental Figure 16:



Supplemental Figure 16. ChIP qPCR data on two regulated genes. I-CBP112-induced reduction of P300-binding to gene loci of ID2 and TNFSF13B. ChIP qPCR from different gene regions of the ID2 and the TNFSF13B locus after treatment with DMSO or 3 μ M I-CBP112 for 8 h (**A**) or 4 days (**B**). The relative enrichment is expressed as mean and error bars represent the standard deviation. DMSO treated cells are indicated by a “-“ and I-CBP112 treated cells by “+”.